Escherichia coli strain for producing 5-aminolevulinic acid through dynamic regulation and control and application thereof

By dynamically regulating the expression of 5-aminolevulinic acid-related genes and weakening the expression of enzymes in downstream metabolic pathways, the high cost and environmental pollution problems of chemical production of 5-aminolevulinic acid are solved, and an efficient and clean biological fermentation method is achieved. Increased yield and simplified the glycine addition step.

CN119060926APending Publication Date: 2024-12-03ANHUI YUANZHI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411121495.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the production of 5-aminolevulinic acid, the chemical method has problems such as many reaction steps, low conversion rate and use of toxic raw materials, resulting in high production costs and environmental pollution, and high yield of engineering strains are added exogenously to glycine. The output increase is limited later.

Method used

Using a dynamic regulation system, the C4 pathway is activated when the glycine concentration is high and the C5 pathway is activated when the glycine concentration is low. In combination with weakening the expression of enzymes related to the downstream metabolic pathway of 5-aminolevulinate in E. coli, the fermentation process is simplified and the glycine conversion rate is improved, thereby improving the 5-Aminolevulinic acid yield.

Benefits of technology

The 5-aminolevulinic acid production was achieved, reaching 61.2g/L in a 5L fermenter, simplifying the glycine addition step, reducing production costs, and providing a more efficient and clean biofermentation method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060926A_ABST
    Figure CN119060926A_ABST
Patent Text Reader

Abstract

The invention discloses an escherichia coli strain for producing 5-aminolevulinic acid through dynamic regulation and control and application of the escherichia coli strain. Specifically, firstly, a dynamic regulation and control system is introduced into escherichia coli, expression of C4 and C5 pathway related enzymes is controlled through a glycine-induced biosensor system, and metabolism of C4 and C5 pathways is balanced, so that the yield of 5-aminolevulinic acid is increased; secondly, expression of 5-aminolevulinic acid downstream metabolic pathway related enzymes in escherichia coli is weakened, and the yield of a target product is further increased. The finally obtained engineering strain can produce 8.4 g / L of 5-aminolevulinic acid under a suitable shake flask fermentation condition, and the yield in a 5L fermentation tank can reach 61.2 g / L.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an Escherichia coli strain producing 5-aminolevulinic acid through dynamic regulation and application thereof, belonging to the field of biotechnology. Background Art

[0002] 5-aminolevulinic acid (5-ALA), as a non-protein amino acid, is an important precursor for the synthesis of pyrrole compounds in organisms, which are important components of cytochromes, hemoglobin, chloroplast proteins, etc. 5-ALA is widely used in medicine, agriculture, animal husbandry and even food and health products, and is an important high-value-added bio-based chemical. The chemical preparation of 5-ALA has many reaction steps, low conversion rate, and the use of toxic raw materials, which will lead to high production costs and cause serious environmental pollution. Therefore, it is imperative to replace the chemical synthesis method with an efficient and clean biological fermentation method to produce 5-ALA.

[0003] In nature, the biosynthesis of 5-ALA mainly includes two pathways: C4 and C5. The C4 pathway is the condensation of succinyl CoA and glycine under the action of 5-aminolevulinic acid synthase (ALAS or hemA) to generate 5-ALA; the C5 pathway uses glutamyl tRNA as a precursor to synthesize 5-ALA through a two-step reaction. Since the steps of the C4 pathway are simple and the substrate can be added exogenously, the resulting 5-ALA yield is much higher than that of the C5 pathway. However, due to the limitations of the metabolic pathway, after reaching a certain level, even if more substrate is added, the 5-ALA yield cannot be increased. At present, the high-yield 5-ALA engineered strains are mainly Escherichia coli engineered strains. By constructing a mutant library for high-throughput screening, the shake flask yield of 5-ALA can reach 14g / L, and the 5L fermentation tank yield is 58.5g / L (ACS SustainableChem.Eng.2024,12,12,4846). However, considering the cost of exogenous addition of glycine during scale-up production and the difficulty of process control, it is necessary to find a new method for producing 5-ALA to overcome the above-mentioned defects. Summary of the invention

[0004] To solve the above problems, the present invention innovatively dynamically regulates the expression of 5-ALA related genes - activating the C4 pathway when the glycine concentration is high, and activating the C5 pathway when the glycine concentration is low, which can simplify the glycine addition step in the fermentation process and improve the glycine conversion rate, thereby increasing 5-ALA production.

[0005] The first object of the present invention is to provide a recombinant Escherichia coli for producing 5-aminolevulinic acid, wherein the recombinant Escherichia coli comprises a dynamic regulation system;

[0006] The dynamic control system comprises:

[0007] A first expression cassette, wherein the first expression cassette contains a gene encoding a glycine-activated riboswitch and a gene encoding a 5-aminolevulinic acid synthase regulated by the gene;

[0008] A second expression cassette, wherein the second expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutamyl-tRNA reductase and a gene encoding a glutaldehyde aminotransferase regulated by the glycine-repressible riboswitch;

[0009] Or the dynamic control system contains:

[0010] A first expression cassette, wherein the first expression cassette contains a gene encoding a glycine-activated riboswitch and a gene encoding a 5-aminolevulinic acid synthase regulated by the gene;

[0011] A second expression cassette, wherein the second expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutamyl-tRNA reductase regulated by the glycine-repressible riboswitch;

[0012] A third expression cassette, wherein the third expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutaldehyde aminotransferase regulated by the glycine-repressible riboswitch;

[0013] The glycine repressible riboswitch encoding gene is composed of a glycine-activated riboswitch encoding gene, a repressor protein encoding gene and a dependent promoter encoding gene. The glycine-activated riboswitch controls the expression of the repressor protein, the dependent promoter initiates the expression of the glutamyl-tRNA reductase encoding gene and / or the glutaldehyde aminotransferase encoding gene, and the repressor protein can inhibit the expression of downstream genes by inhibiting the dependent promoter.

[0014] Furthermore, the recombinant Escherichia coli also includes the following transformation: weakening the expression of at least one of 5-aminolevulinic acid dehydratase (hemB), porphyrinogen deaminase (hemC) and uroporphyrinogen synthase (hemD) in the Escherichia coli host bacteria.

[0015] Further, the weakening method includes but is not limited to replacing a weak RBS sequence, replacing a weak promoter, replacing a start codon, etc., that is, replacing the relevant sequence on the genome. Specifically, the start codon is replaced from ATG to GTG, and / or the RBS of the gene itself is replaced with a weak RBS to reduce the translation strength, and / or, the promoter of the gene itself is replaced with a weak promoter to reduce the transcription strength.

[0016] Furthermore, the repressor protein includes but is not limited to tetracycline repressor protein (tetR), and the dependent promoter includes but is not limited to tetracycline dependent promoter (Ptet).

[0017] Furthermore, the amino acid sequence of the 5-aminolevulinic acid synthase is shown in SEQ ID NO.2, the amino acid sequence of the glutamyl-tRNA reductase is shown in SEQ ID NO.4, and the amino acid sequence of the glutaldehyde aminotransferase is shown in SEQ ID NO.6; the nucleotide sequence of the glycine-activated riboswitch is shown in SEQ ID NO.7, and the nucleotide sequence of the glycine-repressed riboswitch is shown in SEQ ID NO.8.

[0018] Furthermore, the nucleotide sequence of the porphyrinogen deaminase is shown as SEQ ID NO.11, and the weak RBS sequence is shown as SEQ ID NO.9.

[0019] The second object of the present invention is to provide the use of the above-mentioned recombinant Escherichia coli in the preparation of 5-aminolevulinic acid.

[0020] The third object of the present invention is to provide a method for producing 5-aminolevulinic acid, comprising the step of fermenting with the above-mentioned recombinant Escherichia coli.

[0021] Furthermore, the fermentation comprises: inoculating the recombinant E. coli seed liquid into a fermentation medium containing glycine, and inducing expression using an inducer corresponding to the dependent promoter (ie, gene expression after the inducer induces the dependent promoter).

[0022] Furthermore, the fermentation medium containing glycine includes: glucose 10-30 g / L, yeast powder 1-10 g / L, glycine 5-15 g / L, KH2PO4 0.5-2 g / L, Na2HPO4 1-5 g / L, MgSO4 0.1-1 g / L, CaCl2 5-20 mg / L, and NH4Cl 0.1-1 g / L.

[0023] Furthermore, the fermentation is a fed-batch fermentation.

[0024] Furthermore, the fed-batch fermentation comprises the following steps: maintaining the pH at 6.8-7.2 by adding a pH regulator until the batch fermentation is completed.

[0025] Furthermore, the fed-batch fermentation comprises the following steps: when the residual glucose concentration in the fermentation broth drops to 1 g / L or lower, a glucose solution is added to control the glucose concentration in the fermentation broth at 5-10 g / L, and a glycine solution is added at a rate of 3-6 mL / L.

[0026] Furthermore, the concentration of the glucose solution is 400-600 g / L; the concentration of the glycine solution is 100-300 g / L.

[0027] Beneficial effects of the present invention:

[0028] (1) The present invention dynamically regulates the expression of enzymes related to the C4 pathway and the C5 pathway through a glycine-induced biosensor element, thereby adjusting the metabolic balance of the C4 pathway and the C5 pathway, thereby further improving the production of 5-ALA. Specifically, the GlyON promoter is directly used to control the expression of the target gene of the C4 pathway to achieve the ON effect, and the GlyON promoter is directly used to control the inhibitory element corresponding to the target promoter to indirectly control the target gene of the C pathway to achieve the OFF effect.

[0029] (2) Based on dynamic regulation, the present invention reduces the expression of enzymes related to the downstream metabolic pathway of 5-aminolevulinic acid in the 5-aminolevulinic acid production strain, and the yield of the strain in a 5L fermenter can reach 61.2g / L. This lays the foundation for the subsequent industrial scale-up production of 5-aminolevulinic acid. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Schematic diagram of the metabolic pathway of 5-aminolevulinic acid and the schematic diagram of the component construction in the dynamic regulation system.

[0031] Figure 2 This is the plasmid map of pTrc99a-Rp_hemA.

[0032] Figure 3 This is the plasmid map of pTrc99a-GlyON-Rp_hemA.

[0033] Figure 4 This is the plasmid map of pSTV28-GlyOFF-Ec_hemA-hemL.

[0034] Figure 5 The results of 5-aminolevulinic acid production by shake flask fermentation of the control strain and the engineered strain. DETAILED DESCRIPTION

[0035] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0036] The sequence involved in the present invention is as follows:

[0037] (I) Key enzyme sequences and involved element sequences

[0038] Nucleotide sequence of 5-aminolevulinic acid synthase Rp_hemA (SEQ ID NO.1)

[0039]

[0040] Amino acid sequence of 5-aminolevulinic acid synthase Rp_hemA (SEQ ID NO.2)

[0041] MNYEAYFRRQLDGLHREGRYRVFADLERHAGSFPRATHHRPEGAGDVTVWCSNDYLGMGQHPAVLTAMHEALDSCGAGAGGTRNIAGTNHYHVLLEQELAALHGKES ALLFTSGYVSNWASLSTLASRMPGCVILSDELNHASMIEGIRHSRSETRIFAHNDPRDLERKLADLDPHAPKLVAFESVYSMDGDIAPIAEICDVADAHNAMTYLDEV HGVGLYGPNGGGIADREGISHRLTIIEGTLAKAFGVVGGYIAGSSAVCDFVRSFASGFIFSTSPPPAVAAGALASIRHLRASSAERERHQDRVARLRARLDQAGVAHM PNPSHIVPVMVGDAALCKQISDELISRYGIYVQPINYPTVPRGTERLRITPSPQHTDADIEHLVQALSEIWTRVGLAKAA Nucleotide sequence of glutamyl-tRNA reductase Ec_hemA (SEQ IDNO.3)

[0042]

[0043] Amino acid sequence of glutamyl-tRNA reductase Ec_hemA (SEQ ID NO.4)

[0044] MTLLALGINHKTAPVSLRERVSFSPDKLDQALDSLLAQPMVQGGVVLSTCNRTELYLSVEEQDNLQEALIRWLCDYHNLNEEDLRKSLYWHQDNDAVSHLMRVA SGLDSLVLGEPQILGQVKKAFADSQKGHMKASELERMFQKSFSVAKRVRTETDIGASAVSVAFAACTLARQIFESLSTVTVLLVGAGETIELVARHLREHKVQKM IIANRTRERAQILADEVGAEVIALSDIDERLREADIIISSTASPLPIIGKGMVERALKSRRNQPMLLVDIAVPRDVEPEVGKLANAYLYSVDDLQSIISHNLAQRKAAAVEAETIVAQETSEFMAWLRAQSASETIREYRSQAEQVRDELTAKALAALEQGGDAQAIMQDLAWKLTNRLIHAPTKSLQQAARDGDNERLNILRDSLGLE

[0045] Nucleotide sequence of glutaldehyde aminotransferase heml (SEQ ID NO.5)

[0046]

[0047] Amino acid sequence of glutaldehyde aminotransferase heml (SEQ ID NO.6)

[0048] MSKSENLYSAARELIPGGVNSPVRAFTGVGGTPLFIEKADGAYLYDVDGKAYIDYVGSWGPMVLGHNHPAIRNAVIEAAERGLSFGAPTEMEVKMAQLVTELVPTMDMVRMVNSGTEATMSAIRLARGFTGRDKIIKFEGCYHGHADCLLVKAGSGALTLGQPNSPGVPADFAKYTLTCTYNDLASVRAAFEQYPQEIAC IIVEPVAGNMNCVPPLPEFLPGLRALCDEFGALLIIDEVMTGFRVALAGAQDYYGVVPDLTCLGKIIGGGMPVGAFGGRRDVMDALAPTGPVYQAGTLSGNPIAMAAGFACLNEVAQPGVHETLDELTTRLAEGLLEAAEEAGIPLVVNHVGGMFGIFFFTDAESVTCYQDVMACDVERFKRFFHMMLDEGVYLAPSAFEA

[0049] GFMSVAHSMEDINNTIDAAR

[0050] RVFAKL

[0051] Nucleotide sequence of GlyON sensor element (SEQ ID NO.7)

[0052] TTGACGGCTAGCTCAGTCCTAGGTACAGTGCTAGCTTGCTGTTGCCCAGCATATAGTGATGATGGTAGGATATGAGTATGTATTTGATGTAAGATATTGCTATAGTATGTCCATAACAGCATGAAAATATGAGCGAATGACAGCAAGGGGAGAGACCTGACCGAAAACCTCGGGATACAGGCGCCGAAGGAGCAAACTGCGGAGTGAATCTCTCAGGCAAAAGAACTCTTGCTCGACGCAACTCTGGAGAGTGTTTGTGCGGATGCGCAAACCACCAAAGGGGACGTCTTTGCGTATGCAAAGTAAACTTTCAGGTGCCAGGACAGAGAACCTTCATTTTACATGAGGTGTTTCTCTGTCCTTTTTTGTATGTTTTTTAGCTGCGCCGTTGATAAAGGGGAGGAATTAG

[0053] Nucleotide sequence of the GlyOFF sensor element (SEQ ID NO.8)

[0054]

[0055] Replaced weak RBS sequence (SEQ ID NO.9)

[0056] TTCGTAATTCGCAACTGGAACACGCACGCT

[0057] hemC original RBS sequence (SEQ ID NO.10)

[0058] TCTGGCAAGGATGTTAGGATGGACCACGGATGATAATGACGGTAAC AAGC

[0059] Nucleotide sequence of hemC gene (SEQ ID NO.11)

[0060] ATGTTAGACAATGTTTTAAGAATTGCCACACGCCAAAGCCCACTTGCACTCTGGCAGGCACACTATGTCAAAGACAAGTTGATGGCGAGCCATCCGGGCCTGGTCGTTGAACTGGTACCGATGGTGACGCGCGGCGATGTGATTCTTGATACGCCGCTGGCGAAAGTAGGCGGAAAAGGCTTATTTGTAAAAGAGCTGGAAGTCGCGCTCCTCGAAAATCGCGCCGATATCGCCGTACACTCAATGAAAGATGTGCCGGTTGAATTCCCGCAAGGTCTGGGACTGGTCACTATTTGTGAGCGTGAAGATCCTCGCGATGCCTTTGTGTCCAATAACTATGACAGTCTGGATGCGTTACCGGCAGGCAGTATCGTCGGGACGTCCAGTTTACGTCGCCAGTGCCAACTGGCTGAACGCCGTCCGGATCTGATTATCCGCTCCCTGCGCGGCAACGTCGGCACTCGCCTGAGCAAACTGGATAACGGCGAATACGATGCCATCATTCTTGCCGTAGCCGGACTAAAACGTTTAGGTCTGGAGTCACGTATTCGCGCCGCGTTGCCACCCGAGATTTCTCTTCCGGCGGTAGGACAAGGTGCGGTGGGTATTGAATGCCGCCTTGATGATTCACGCACTCGCGAGCTGCTTGCCGCGCTGAATCACCACGAAACTGCACTGCGCGTTACCGCAGAACGCGCCATGAATACCCGTCTCGAAGGCGGATGTCAGGTGCCAATTGGTAGCTACGCCGAGCTTATTGATGGCGAAATCTGGCTGCGTGCGCTGGTCGGCGCGCCGGACGGTTCGCAGATTATTCGCGGTGAACGCCGCGGTGCGCCGCAAGATGCCGAACAAATGGGGATTTCGCTGGCAGAAGAGCTACTGAATAACGGCGCGCGCGAGATCCTCGCTGAAGTCTATAACGGAGACGCCCCGGCATGA

[0061] (II) Primer sequences

[0062]

[0063]

[0064] Example 1 Construction of overexpression plasmid vectors pTrc99a-Rp_hemA, pTrc99a-GlyON-Rp_hemA and pSTV28-GlyOFF-Ec_hemA-hemL

[0065] The 5-aminolevulinic acid synthase gene Rp_hemA (nucleotide sequence such as SEQ ID NO.1, amino acid sequence such as SEQ ID NO.2), glutamyl-tRNA reductase gene Ec_hemA (nucleotide sequence such as SEQ ID NO.3, amino acid sequence such as SEQ ID NO.4), glutaldehyde aminotransferase gene heml (nucleotide sequence such as SEQ ID NO.5, amino acid sequence such as SEQ ID NO.6), glycine-induced activation sensor element GlyON (nucleotide sequence such as SEQ ID NO.7) and glycine-induced inhibition sensor element GlyOFF (nucleotide sequence such as SEQ ID NO.8) of Rhodopseudomonas palustris were synthesized separately by the whole gene synthesis method.

[0066] (1) Construction of pTrc99a-Rp_hemA plasmid

[0067] Rp_hemA was amplified by PCR using primers Rp_hemA-F1 / Rp_hemA-R, and the empty plasmid vector pTrc99a was amplified by PCR using primers pTrc99a-F / pTrc99a-R1. The two PCR products were detected by 1.0% agarose gel electrophoresis and the fragments were purified using a clean-up kit. The two recovered fragments were then connected by homologous recombination using a kit, and the connection products were transformed into DH5α competent cells, coated on ampicillin-resistant plates for overnight culture, and positive clones were selected for colony PCR verification. The correct transformants were sequenced for verification, and the correct recombinant vector was named pTrc99a-Rp_hemA. The plasmid map is shown in the figure. Figure 2 .

[0068] (2) Construction of pTrc99a-GlyON-Rp_hemA plasmid

[0069] GlyON was amplified by PCR using primers GlyON-F / GlyON-R, and plasmid vector pTrc99a-Rp_hemA was amplified by PCR using primers Rp_hemA-F2 / pTrc99a-R2. The two PCR products were detected by 1.0% agarose gel electrophoresis and the fragments were purified using a clean-up kit. The two recovered fragments were then connected by homologous recombination using a kit, and the connection products were transformed into DH5α competent cells, coated on ampicillin-resistant plates for overnight culture, and positive clones were selected for colony PCR verification. The correct transformants were sequenced for verification, and the correct recombinant vector was named pTrc99a-GlyON-Rp_hemA. The plasmid map is shown in Figure 3 .

[0070] (3) Construction of pSTV28-GlyOFF-Ec_hemA-hemL plasmid

[0071] PCR amplification was performed using primers Ec_hemA-F / Ec_hemA-R and heml-F / hemL-R with the Escherichia coli MG1655 genome as a template, and primers GlyOFF-F / GlyOFF-R and pSTV28-F / pSTV28-R were used to PCR amplify GlyOFF and the empty plasmid vector pSTV28, respectively. The four PCR products obtained were detected by 1.0% agarose gel electrophoresis and the fragments were purified using a clean-up kit. The recovered four fragments were then homologously recombined and connected using a kit, and the connection products were transformed into DH5α competent cells, coated with chloramphenicol resistant plates for overnight culture, and positive clones were selected for colony PCR verification. The correct transformants were sequenced for verification, and the correct recombinant vector was named pSTV28-GlyOFF-Ec_hemA-hemL. The plasmid map is shown in Figure 4 .

[0072] Example 2 Effect of reducing the expression of enzymes related to the downstream metabolic pathway of 5-ALA in Escherichia coli on the production of 5-ALA

[0073] (1) Replace the original RBS of the hemC gene with a weak RBS sequence and replace the start codon with GTG

[0074] The original RBS of the hemC gene was replaced by homologous recombination (see PNAS, 2000, 97(12):6640). The weak RBS sequence is SEQ ID NO.9, the original RBS sequence of the hemC gene to be replaced is SEQ ID NO.10, and the original sequence of the hemC gene is SEQ ID NO.11.

[0075] Using the genome of Escherichia coli W3110 as a template, hemC-LH-F / hemC-LH-R were used as primers to amplify the upstream fragment of the gene hemC, and hemC-RH-F / hemC-RH-R were used as primers to amplify the downstream fragment of the gene hemC. At the same time, FRT-Kan-F / FRT-Kan-R were used as primers to amplify the empty plasmid vector pKD4. The three PCR products obtained were detected by 1.0% agarose gel electrophoresis and the fragments were purified with a clean-up kit. Then the three fragments recovered were subjected to fusion PCR using primers hemC-LH-F / hemC-RH-R, and the product hemC-Kan was detected by 1.0% agarose gel electrophoresis and purified with a clean-up kit.

[0076] The hemC-Kan fragment was transferred into the competent E. coli W3110 carrying pKD46 and induced, and the positive clones with successful recombination were screened by kanamycin and colony PCR. The selected transformants were then transferred into the plasmid pCP20 to eliminate the kanamycin marker. The colonies grown on the plate were spotted on the LB solid plate without kanamycin and the LB solid plate containing 50μg / mL kanamycin. The colonies that grew on the plate without kanamycin but did not grow on the kanamycin plate were selected for PCR verification, and the hemC gene weakened strain was obtained, and the pCP20 and pKD46 plasmids were eliminated by heating to obtain the strain ALA1.

[0077] (2) The effect of reducing the expression of enzymes related to the downstream metabolic pathway of 5-ALA in Escherichia coli on 5-ALA production

[0078] The above recombinant vector pTrc99a-Rp_hemA was transformed into Escherichia coli W3110 and ALA1, respectively, to obtain the control strain W3110 / pTrc99a-Rp_hemA and the engineered strain ALA1 / pTrc99a-Rp_hemA. The above two bacteria were inoculated into 5 mL of LB liquid culture medium containing 100 μg / mL ampicillin, cultured at 37°C 200rpm for 16 hours, and then transferred to a 250 mL Erlenmeyer flask containing 30 mL of fermentation medium at 1% (v / v). After culturing at 37°C 200rpm for 4 hours, an inducer with a final concentration of 100 μM was added, and the fermentation broth was collected after 48 hours of induction culture to detect the concentration of 5-ALA.

[0079] The shake flask fermentation medium formula is: glucose 20g / L, yeast powder 5g / L, glycine 10g / L, KH2PO4 1g / L, Na2HPO4 3g / L, MgSO4 0.24g / L, CaCl2 11mg / L, NH4Cl 0.5g / L, and the final concentration of ampicillin is 100μg / mL.

[0080] The detection method of 5-ALA is as follows: take 40 μl of fermentation liquid, add 160 μl of 0.2M sodium bicarbonate solution, then add 200 μl of 0.1M dansyl chloride solution, mix well and place in a water bath at 30 degrees for 30 minutes, then add 400 μl of 0.12M hydrochloric acid solution, and perform HPLC detection after passing through a membrane.

[0081] The shake flask fermentation results are shown in Figure 5 The 5-ALA production of the control strain W3110 / pTrc99a-Rp_hemA was 1.2 g / L, and the production of the engineered strain ALA1 / pTrc99a-Rp_hemA reached 6.1 g / L.

[0082] Example 3 Effect of Dynamic Regulation of Expression of C4 Pathway and C5 Pathway Related Enzymes on 5-ALA Production Using Glycine-Induced Sensor Elements

[0083] (1) Shake flask testing of the effects of glycine-induced sensor elements on the dynamic regulation of the expression of C4 and C5 pathway-related enzymes on 5-ALA production

[0084] The recombinant vectors pTrc99a-GlyON-Rp_hemA and pSTV28-GlyOFF-Ec_hemA-hemL in Example 1 were co-transformed into Escherichia coli W3110 and ALA1, respectively, to obtain the control strain W3110 / Gly-C4-C5 and the engineered strain ALA1 / Gly-C4-C5. The two bacteria were inoculated into 5 mL of LB liquid medium containing 100 μg / mL ampicillin and 30 μg / mL, cultured at 37°C 200rpm for 16 hours, and then transferred to a 250 mL Erlenmeyer flask containing 30 mL of fermentation medium at 1% (v / v), cultured at 37°C 200rpm, and glycine was added every 12 hours to a final concentration of 5 g / L. The fermentation broth was collected after 48 hours to detect the concentration of 5-ALA. The culture medium formula and detection method were the same as those in Example 2. The 5-ALA yields of the control strain W3110 / Gly-C4-C5 and the engineered strain ALA1 / Gly-C4-C5 were 1.8 g / L and 8.4 g / L, respectively.

[0085] (2) Detection of the effect of glycine-induced sensor elements on the expression of C4 and C5 pathway-related enzymes on 5-ALA production at the 5L fermentation tank level

[0086] The above recombinant engineering strain ALA1 / Gly-C4-C5 was inoculated into a seed culture medium, and cultured on a shaking table at 37°C and 200rpm for 24 hours. The seed solution was inoculated into a 5L fermenter containing 2L fermentation medium at 10% (v / v). The fed-batch fermentation of the present invention was carried out at 37°C, and the pH in the fermentation system was maintained at pH 7.0 by automatically adding 25% ammonia water. The air flow rate range was 1.0-2.0 vvm (air volume / working volume / minute). During the whole fermentation process, glycine was added with a uniform flow of mother liquor at a rate of 4.6 mL / L. When the glucose concentration in the culture medium was reduced to 1 g / L, the feed culture medium solution was added and the residual glucose concentration was adjusted to 5-10 g / L. After fermentation for 72 hours, the 5-ALA yield reached 61.2 g / L.

[0087] The seed culture medium is an LB liquid culture medium containing 100 μg / mL ampicillin and 30 μg / mL chloramphenicol. The fermentation culture medium formula is the same as the shake flask fermentation culture medium formula in Example 2, with the addition of 100 μg / mL ampicillin and 30 μg / mL chloramphenicol. The glycine mother solution is a 150 g / L glycine solution. The fermentation feed medium is a 500 g / L glucose solution.

[0088] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A recombinant Escherichia coli for producing 5-aminolevulinic acid, It is characterized in that The recombinant Escherichia coli includes a dynamic regulatory system; The dynamic control system comprises: A first expression cassette, wherein the first expression cassette contains a gene encoding a glycine-activated riboswitch and a gene encoding a 5-aminolevulinic acid synthase regulated by the gene; A second expression cassette, wherein the second expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutamyl-tRNA reductase and a gene encoding a glutaldehyde aminotransferase regulated by the glycine-repressible riboswitch; Or the dynamic control system contains: A first expression cassette, wherein the first expression cassette contains a gene encoding a glycine-activated riboswitch and a gene encoding a 5-aminolevulinic acid synthase regulated by the gene; A second expression cassette, wherein the second expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutamyl-tRNA reductase regulated by the glycine-repressible riboswitch; A third expression cassette, wherein the third expression cassette contains a gene encoding a glycine-repressible riboswitch and a gene encoding a glutaldehyde aminotransferase regulated by the glycine-repressible riboswitch; The glycine repressible riboswitch encoding gene is composed of a glycine-activated riboswitch encoding gene, a repressor protein encoding gene and a dependent promoter encoding gene. The glycine-activated riboswitch controls the expression of the repressor protein, the dependent promoter initiates the expression of the glutamyl-tRNA reductase encoding gene and / or the glutaldehyde aminotransferase encoding gene, and the repressor protein can inhibit the expression of downstream genes by inhibiting the dependent promoter.

2. The recombinant Escherichia coli according to claim 1, It is characterized in that The recombinant Escherichia coli also includes the following transformation: weakening the expression of at least one of 5-aminolevulinic acid dehydratase, porphyrinogen deaminase and uroporphyrinogen synthase in the Escherichia coli host bacteria.

3. The recombinant Escherichia coli according to claim 2, It is characterized in that The weakening method includes at least one of replacing a weak RBS sequence, replacing a weak promoter, and replacing a start codon.

4. The recombinant Escherichia coli according to claim 1, It is characterized in that The repressor protein comprises a tetracycline repressor protein, and the dependent promoter comprises a tetracycline-dependent promoter.

5. The recombinant Escherichia coli according to claim 1, It is characterized in that The amino acid sequence of the 5-aminolevulinic acid synthase is shown in SEQ ID NO.2, the amino acid sequence of the glutamyl-tRNA reductase is shown in SEQ ID NO.4, and the amino acid sequence of the glutaldehyde aminotransferase is shown in SEQ ID NO.6; the nucleotide sequence of the glycine-activated riboswitch is shown in SEQ ID NO.7, and the nucleotide sequence of the glycine-repressed riboswitch is shown in SEQ ID NO.

8.

6. Use of the recombinant Escherichia coli according to any one of claims 1 to 5 in the preparation of 5-aminolevulinic acid.

7. A method for producing 5-aminolevulinic acid, It is characterized in that The method comprises the step of fermenting with the recombinant Escherichia coli according to any one of claims 1 to 5.

8. The method according to claim 7, It is characterized in that The fermentation comprises: inoculating the recombinant Escherichia coli seed liquid into a fermentation medium containing glycine, and inducing expression by using an inducer corresponding to the dependent promoter.

9. The method according to claim 7, It is characterized in that The fermentation was a fed-batch fermentation.

10. The method according to claim 9, It is characterized in that The fed-batch fermentation comprises at least one of the following: (1) maintaining the pH at 6.8-7.2 by adding a pH regulator until the end of batch fermentation; (2) When the residual glucose concentration in the fermentation broth drops to 1 g / L or lower, a glucose solution is added to control the glucose concentration in the fermentation broth at 5-10 g / L, and a glycine solution is added at a rate of 3-6 mL / L.